Prednisolone Trial in Children Younger Than 4 Years

Nephrotic Syndrome Clinical Trial

Official title:

Randomized, Multicentric, Open Label, Parallel Group Trial to Compare the Efficacy of 6-months Versus 3-months Therapy With Prednisolone for the First Episode of Idiopathic Nephrotic Syndrome in Children Younger Than 4 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03141970
• Other study ID #: v1.0
• Secondary ID: CTRI/2015/06/005
• Status: Completed
• Phase: Phase 3
• Start date: July 1, 2015
• Est. completion date: October 31, 2021

Study information

• Verified date: January 2024
• Source: All India Institute of Medical Sciences, New Delhi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multicentric, randomized, parallel group, open label controlled trial of children age 1 year up to 4 years with new onset, idiopathic nephrotic syndrome. It is designed to test the initial duration of steroid therapy of either 3 month or 6 month total duration. Participants will be randomized to either extend their pre-trial 3 months (12 weeks) of standard of care corticosteroid therapy to add an additional 12 weeks of therapy or to stop therapy. Pre-trial standard of care corticosteroids will include 60 mg/m2/day for 6 weeks followed by 40 mg/m2/day every other day for 6 weeks of prednisolone or equivalent. The trial intervention will therefore be an additional 12 vs 0 weeks of corticosteroids in these children with idiopathic nephrotic syndrome.

Description:

Trial Registration Note:This trial was initially registered in the Indian Registry (list the number) on (date) prior to enrolling participants. The present listing shows this status of currently enrolling. New sites in the United States are expected to open within the coming year. At that time the answers to some questions, such as "Studies FDA regulated drug" will change because the basis for FDA regulation will reside on the presence of US sites and the use of US manufactured drug, whereas at this time the drug is not of US manufacture, and the trial is not currently conducted in the United States. This registration is being posted at this time to prepare to meet United States FDAAAA registration requirements.

Nephrotic syndrome is a common renal disorder in children characterized by proteinuria, hypoalbuminemia and edema. The long-term prognosis for steroid-sensitive nephrotic syndrome is excellent for resolution of disease and maintenance of renal function. About 80% patients with steroid-sensitive nephrotic syndrome will relapse one or more times, requiring repeated treatment with corticosteroids. Of these, 50-60% show frequent relapses or steroid dependence and require therapy with long-term corticosteroids and other medications. Patients with multiple relapses are at risk for life-threatening infections, malnutrition and thrombotic episodes. They are also likely to show serious side effects of long-term steroid therapy and those related to use of other medications, including toxicity to bone marrow, gonads, central nervous system and kidneys. Repeated relapses also result in multiple hospitalizations and school absence. Strategies effective in reducing relapse rates and proportion of patients with frequent relapses or steroid dependence shall therefore be extremely valuable in improving the long-term management of nephrotic syndrome.

Based on information from multiple studies that prolonged duration of initial therapy beyond 8-weeks reduced the risk of an early relapse and lowered frequency of subsequent relapses, it is agreed upon that the initial therapy with prednisolone should continue for 12 weeks (3 months), administered daily for a duration of 6 weeks, and then on alternate days for another 6 weeks. However, the optimal dose and duration of corticosteroid therapy remains to be determined. Data from various prospective studies, systematically reviewed in the Cochrane Registry, suggests the beneficial effects of prolongation of treatment beyond 3 months, with benefit seen up to 6-months. However, the advantages of extending therapy from 3- to 6-months are not unambiguous; there are also concerns of the corticosteroid toxicity with the latter regimens. Recent placebo controlled trials reported in 2013, including from this center, suggest that extending initial prednisolone treatment from 3 months to 6 months, with or without an increase in cumulative dose, does not influence the course of disease in children with nephrotic syndrome. However, in the study conducted in India, we found that prolonged therapy was useful in postponing the first relapse, and was associated with an insignificantly decreased risk of frequent relapses, in the subgroup of children younger than 4 years. Since the subgroups were not defined a priori, a prospective study is required to clarify the efficacy of this intervention in young patients.

Further, the lack of clarity regarding disease pathogenesis makes the administration of corticosteroid therapies largely empirical. While clear insight into the pathogenic pathways targeted by prednisolone is lacking, there is some evidence that disease remission is associated with down regulation of T cell activation, altered B-T cell crosstalk, upregulation of T helper type 1(Th1) and/or T regulatory compartments.

This present study proposes to examine the benefits of prolongation of initial therapy of idiopathic nephrotic syndrome from the current standard of 3 to 6 months among children younger than 4-yr-old an onset of disease. Prolongation of treatment at the first episode would have considerable promise, if found effective in reducing future relapses and without concomitant risks of corticosteroid toxicity. The proposal also aims to examine the proportions of T and B lymphocyte subsets in 20 patients with the initial episode of nephrotic syndrome. The evaluation shall be conducted at onset of disease, following prednisolone induced disease remission, and at one year from randomization or at first relapse of the disease to determine differences in the immune profiles at different stages of the disease. Apart from improving our knowledge of pathogenesis of nephrotic syndrome, this approach shall enhance our understanding of the immunological alterations influenced by therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 170
• Est. completion date: October 31, 2021
• Est. primary completion date: October 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 4 Years

Eligibility

Inclusion Criteria:

1. Idiopathic, steroid-sensitive, first episode of nephrotic syndrome

2. Age 12 months up to 48 months

3. Written informed consent

Exclusion Criteria

1. Nephrotic syndrome known to be secondary to a systemic disorder, e.g., Immunoglobulin A (IgA) nephropathy, systemic lupus erythematosus, Henoch Schonlein purpura, vasculitis, , hepatitis B or Alport syndrome.

2. Persistent estimated glomerular filtration rate (GFR) <75 ml/min/1.73 m2,

3. Therapy with prednisolone for prior episodes of nephrotic syndrome,

4. Therapy with corticosteroids in the past 3 months, in a dose more than 1 mg/kg for >14 days for any other reason,

5. Corticosteroid therapy for initial episode of nephrotic syndrome prior to randomization varying from pre-specified protocol on more than 14 days,

6. Patients who show relapse during the first 3 months of pre-randomization corticosteroid therapy for nephrotic syndrome,

7. Unclear treatment history,

8. Gross hematuria,

9. Patients with initial steroid resistance,

10. Participation in any other drug study during the course of this study.

11. Participation in more than one study without approval from the researchers involved in each study,

Related Conditions & MeSH terms

• Nephrosis
• Nephrotic Syndrome
• Syndrome

Intervention

Drug:
• Prednisolone
Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks

Locations

Country	Name	City	State
India	All India Institute of Medical Sciences	New Delhi	Delhi
United States	University of Michigan Department of Pedatric Nephrology	Ann Arbor	Michigan
United States	Levine's Children/Carolinas HealthCare System	Charlotte	North Carolina
United States	Cedars-Sinai Medical Center, Pediatric IBD & Pediatric Nephrology	Los Angeles	California
United States	Stanford University Medical Center, Department of Pediatrics, Division of Nephrology	Stanford	California

Sponsors (4)

Lead Sponsor	Collaborator
All India Institute of Medical Sciences, New Delhi	Department of Biotechnology, Government of India (funding agency), NephCure Accelerating Cures Institute, University of Michigan

Countries where clinical trial is conducted

United States,  India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	In a subgroup of 20 patients, the proportions of the following cell subsets, at baseline and at 6 and 12 months after randomization and at first relapse	Proportions of B (naive, memory, regulatory) and T (cytotoxic, helper 1, helper 2, helper 17, regulatory) cell subsets, as determined by flow cytometric staining for specific surface and intracellular markers	12 month period following randomization
Other	Relapse of nephrotic syndrome during 24 months after randomization	Proportion of patients with one or more relapse(s) of nephrotic syndrome	24 month period following randomization
Other	Number of relapses during 24 months follow up	Number of nephrotic syndrome relapses per patient year during the 24-month period	24 month period following randomization
Other	Time to first relapse (days)	Number of days from randomization to occurrence of first relapse	24 month period following randomization
Other	Occurrence of frequent relapses of nephrotic syndrome during 24 months from randomization	Proportion of patients with frequent relapses during the 24 months post randomization	24 month period following randomization
Other	Cumulative prednisolone [or corticosteroid equivalent] received during 24 month period	Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 24 months from randomization	24 month period following randomization
Other	Relapse of nephrotic syndrome during 12 months after randomization in boys compared to girls	Proportion of patients with one or more relapse(s) of nephrotic syndrome in boys compared to girls	12 month period following randomization
Other	Relapse of nephrotic syndrome during 12 months after randomization in patients <2-yr-old at randomization compared to older patients	Proportion of patients with one or more relapse(s) of nephrotic syndrome in patients <2-yr-old at randomization compared to older patients	12 month period following randomization
Other	Relapse of nephrotic syndrome during 12 months after randomization in Indian patients compared to those in the USA	Proportion of patients with one or more relapse(s) of nephrotic syndrome in Indian patients compared to those in the USA	12 month period following randomization
Other	Number of relapses during 12 months follow up in boys compared to girls	Number of nephrotic syndrome relapses per patient year during the 12-month period in boys compared to girls	12 month period following randomization
Other	Number of relapses during 12 months follow up in patients <2-yr-old at randomization compared to older patients	Number of nephrotic syndrome relapses per patient year during the 12-month period in patients <2-yr-old at randomization compared to older patients	12 month period following randomization
Other	Number of relapses during 12 months follow up in Indian patients compared to those in the USA	Number of nephrotic syndrome relapses per patient year during the 12-month period in Indian patients compared to those in the USA	12 month period following randomization
Other	Time to first relapse (days) in boys compared to girls	Number of days from randomization to occurrence of first relapse in boys compared to girls	12 month period following randomization
Other	Time to first relapse (days) in patients <2-yr-old at randomization compared to older patients	Number of days from randomization to occurrence of first relapse in patients <2-yr-old at randomization compared to older patients	12 month period following randomization
Other	Time to first relapse (days) in Indian patients compared to those in the USA	Number of days from randomization to occurrence of first relapse in Indian patients compared to those in the USA	12 month period following randomization
Other	Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization in boys compared to girls	Proportion of patients with frequent relapses during the 12 months post randomization in boys compared to girls	12 month period following randomization
Other	Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization in patients <2-yr-old at randomization compared to older patients	Proportion of patients with frequent relapses during the 12 months post randomization in patients <2-yr-old at randomization compared to older patients	12 month period following randomization
Other	Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization in Indian patients compared to those in the USA	Proportion of patients with frequent relapses during the 12 months post randomization in Indian patients compared to those in the USA	12 month period following randomization
Other	Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period in boys compared to girls	Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization in boys compared to girls	12 month period following randomization
Other	Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period in patients <2-yr-old at randomization compared to older patients	Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization in patients <2-yr-old at randomization compared to older patients	12 month period following randomization
Other	Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period in Indian patients compared to those in the USA	Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization in Indian patients compared to those in the USA	12 month period following randomization
Primary	Relapse of nephrotic syndrome during 12 months after randomization	Proportion of patients with one or more relapse(s) of nephrotic syndrome	12 month period following randomization
Secondary	Number of relapses during 12 months follow up	Number of nephrotic syndrome relapses per patient year during the 12-month period following randomization	12 month period following randomization
Secondary	Time to first relapse (days)	Number of days from randomization to occurrence of first relapse	12 month period following randomization
Secondary	Occurrence of frequent relapses of nephrotic syndrome during 12 months from randomization	Proportion of patients with frequent relapses during the 12 months post randomization	12 month period following randomization
Secondary	Cumulative prednisolone [or corticosteroid equivalent] received during 12 month period from randomization	Total amount of prednisolone [or corticosteroid equivalent] received, as mg/kg/day or mg/m2/day as intervention and for treatment of relapses, during 12 months from randomization	12 month period following randomization
Secondary	The use of steroid-sparing medications	The proportion of patients in each study arm treated with steroid-sparing strategies or medications, e.g., levamisole, cyclophosphamide, mycophenolate mofetil and calcineurin inhibitors	12 month period following randomization
Secondary	Adverse events during 12-month period after randomization	Number and types of adverse events experienced, related or unrelated to corticosteroid use	12 month period following randomization
Secondary	Change in anthropometry and growth velocity during 12-month period after randomization	Changes in standard deviation scores (SDS) for weight, height and body mass index during 12-month period following randomization	12 month period following randomization